Using monoclonal antibodies to treat yellow fever infections
Learning from the Ebola success: Can a mAb also save lives after yellow fever infection?
This study is looking at a new treatment using a special antibody to help people with yellow fever, especially in places where vaccines aren't widely used, to see if it can lower the virus in their bodies and help them recover better.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Mabloc, LLC NIH-funded |
| Lab location | 1 site (Washington, United States) |
| Project ID | NIH-10669613 on NIH RePORTER |
What this research studies
This research investigates the potential of a monoclonal antibody (mAb) to treat patients infected with the yellow fever virus, similar to successful treatments for Ebola. The approach involves administering a specific mAb to reduce the viral load and improve survival rates in infected individuals. The study aims to address the lack of effective treatments for yellow fever, especially in areas where vaccination coverage is low due to adverse effects. By leveraging previous successes with mAbs in Ebola treatment, the research seeks to develop a viable therapeutic option for yellow fever patients.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with yellow fever, particularly those who are hospitalized and at high risk of severe outcomes.
Not a fit: Patients who have already been vaccinated against yellow fever and are not currently infected may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a new treatment option that significantly reduces mortality rates in yellow fever patients.
How similar studies have performed: Previous research has shown success in using monoclonal antibodies for treating Ebola, indicating a promising approach for similar viral infections like yellow fever.
Where this research is happening
Washington, United States
- Mabloc, LLC — Washington, United States (Active)
Researchers
- Principal investigator: Watkins, David I — Mabloc, LLC
- Study coordinator: Watkins, David I
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.